EU approves first CAPS drugs
This article was originally published in Scrip
Executive Summary
The European Commission has approved two drugs for the treatment of cryopyrin-associated periodic syndrome (CAPS), Novartis's Ilaris (canakinumab) and Regeneron Pharmaceuticals' Arcalyst (rilonacept).